Duanfang Zhou is a medical doctor specializing in anti-tumor pharmacology at the Women and Children’s Hospital of Chongqing Medical University. Her research focuses on identifying novel therapeutic targets and elucidating their mechanisms in breast cancer development. She is also focus on the discovery and development of new anti-cancer agents, aiming to advance personalized and precision cancer therapy through translational research.

Dr. Xiaolei Zhang is a Professor at the School of Pharmaceutical Sciences, Sun Yat-sen University. He has been repeatedly recognized as one of the world’s top 2% most influential scientists. Dr. Zhang holds several key leadership roles in professional societies, including Executive Council Member of the Guangdong Pharmacological Society, Vice Chair of its Marine Drug Pharmacology Committee, Vice Chair of the Experimental Medicine Committee of the Guangdong Association of Integrated Traditional Chinese and Western Medicine, Vice Chair of the Liver Disease Diagnosis, Treatment & Clinical Research Committee of the Guangdong Clinical Medical Society, and Vice Chair of the Pediatric Hematology–Oncology Expert Committee of the Guangdong Pharmaceutical Society. His research focuses on innovative drug discovery and pharmacological studies. His team has identified novel molecular targets implicated in cancer recurrence, metastasis, drug resistance, and blinding ocular diseases—with a particular emphasis on historically “undruggable” targets.

Wang Jiaxing, a doctoral student at Harbin Medical University. Research support units: National Key Laboratory of Cold Region Cardiovascular Diseases at Harbin Medical University, Key Laboratory of Intestinal Microbiota and Pharmacogenomics in Heilongjiang Province, National Provincial Key Laboratory of Biomedicine in China, and the Center for Infection and Genomics of the Karagali University College of Medicine at the University of Calgary. The research field of this project focuses on the treatment of ovarian cancer, and the research direction is dedicated to the intestinal microbiota metabolites of natural plant lignans - intestinal esters. It explores the pharmacological activity and target points of these substances in the treatment of ovarian cancer, and investigates their efficacy evaluation in the process of fighting ovarian cancer and the exploration of potential pharmacological mechanisms.

Wentao Jin is a PhD candidate in pharmaceutical sciences at the University of Sydney, Australia. His research centers on the discovery and preclinical evaluation of novel therapeutics for human uveal melanoma (UM), a rare yet highly aggressive ocular cancer with limited treatment options. By integrating natural product-derived compounds, mechanistic cell biology, and drug–target interaction studies, his work aims to identify innovative therapeutic strategies to overcome treatment resistance and metastatic progression. Wentao’s research interests span anticancer drug development and molecular pharmacology, with an emphasis on bridging fundamental mechanisms to clinical relevance. His work contributes to ongoing efforts to discover and develop new therapeutic approaches for uveal melanoma.

Dr Xiuping Chen has been a full professor at the University of Macau since 2021. He has over 20 years' experience in pharmacological research, particularly focusing on screening and identifying regulators of programmed cell death (PCD) and epithelial-mesenchymal transition (EMT) from natural compounds. His work aims to discover lead compounds or potential therapeutics for cancers, cardiovascular diseases and fibrotic disorders. His notable accolades include the 17th SERVIER Young Pharmacologist Award in 2013 and Second Prize in the Macao Science and Technology Awards in 2012 and 2014. He is a Member of the Royal Society of Biology and has been chairman of the Macau Society of Pharmacology and Toxicology since 2024. He is the senior editor of the British Journal of Pharmacology and has authored over 100 publications, which have received more than 17,000 citations. His current h-index is 70.

Ying Shen, PhD, is Professor and Principal Investigator of anti-tumor pharmacology group in Shanghai Jiao Tong University School of Medicine. Dr. Shen earned her PhD in pharmacology at Shanghai Institute of Materia Medica, Chinese Academy of Sciences and completed her postdoctoral training at University of California San Diego (UCSD). She has worked at Shanghai Jiao Tong University School of Medicine since 2009. Her lab focuses on metabolism reprogramming and related molecular mechanisms during targeted drug resistance and tumor metastasis in lung cancer, discovery and development of novel inhibitors targeting key enzymes in cancer cell metabolism. Relevant works have been published in high-rank SCI journals such as Cell Metabolism (2019), Science Translational Medicine (2021), Cancer Research (2022, Cover article), Oncogene (2024), Drug Resistance Updates (2023), and have granted five patents. The cooperation potent have signed a transformation cooperation agreement.